ozenoxacin and Streptococcal-Infections

Ozenoxacin, a novel topical antibacterial agent with potent bactericidal activity against gram-positive bacteria, has been developed as a cream with 1% active drug for the treatment of impetigo, a highly contagious bacterial skin infection.. To evaluate the efficacy, safety, and tolerability of ozenoxacin cream, 1%, after 5-day twice-daily topical treatment in patients with impetigo.. This randomized, double-blind, vehicle-controlled clinical trial included patients 2 months or older with impetigo who were enrolled at centers in 6 countries from June 2, 2014, through May 30, 2015. Data were analyzed based on intention to treat from July 9 through July 22, 2015.. Patients were randomized 1:1 to receive topical ozenoxacin or placebo control.. Efficacy was measured using the Skin Infection Rating Scale and microbiological culture. Safety and tolerability were also evaluated.. Among the 411 patients who received treatment (210 males [51.1%]; mean [SD] age, 18.6 [18.3] years), ozenoxacin demonstrated superior clinical success compared with placebo, which was evident after 5 days of therapy (112 of 206 [54.4%] vs 78 of 206 [37.9%]; P = .001). Ozenoxacin also demonstrated superior microbiological success compared with placebo after 2 days of therapy (109 of 125 [87.2%] vs 76 of 119 [63.9%]; P = .002). Ozenoxacin was well tolerated, with 8 of 206 patients experiencing adverse effects, with only 1 of these potentially related to the study treatment; none were serious.. Topical ozenoxacin is effective and well tolerated in the treatment of impetigo in patients 2 months and older. This effect is demonstrated by rapid onset of response and superior clinical and microbiological response compared with placebo. Topical ozenoxacin represents a novel option for the treatment of impetigo.. ClinicalTrials.gov Identifier: NCT02090764.

Topics: Adolescent; Adult; Aminopyridines; Anti-Bacterial Agents; Child; Child, Preschool; Double-Blind Method; Drug Resistance, Bacterial; Female; Humans; Impetigo; Infant; Male; Quinolones; Skin Cream; Staphylococcal Infections; Streptococcal Infections; Streptococcus pyogenes; Young Adult

Topics: Aminopyridines; Animals; Anti-Bacterial Agents; Child; Disease Models, Animal; Dogs; Humans; Impetigo; Quinolones; Rats; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes